Hematologic Malignancy
Myeloid Leukemia
CI-CAN-00001251Explore in graph →
Hematologic862 active trials22 approved drugs599 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001251Explore in graph →
Clinical trials
3,530 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00878722 | Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy | completed | Phase 1 / Phase 2 | 41 | Valerio TherapeuticsINDUSTRY | 3 | Jul 28, 2015 | clinicaltrials |
| NCT00565058 | Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML) | completed | Phase 2 | 27 | Aptose Biosciences Inc.INDUSTRY | 1 | Jul 27, 2015 | clinicaltrials |
| NCT00533078 | Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies(LUNCH1) | completed | Phase 2 | 14 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT00469729 | Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy(ExCell) | completed | Phase 2 / Phase 3 | 101 | Gamida Cell -Teva Joint Venture Ltd.OTHER | 5 | Jul 10, 2015 | clinicaltrials |
| NCT00634244 | Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 92 | National Cancer Institute (NCI)NIH | 2 | Jul 7, 2015 | clinicaltrials |
| NCT02363868 | Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population | completed | — | 186 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 7, 2015 | clinicaltrials |
| NCT00324220 | A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 66 | Mirati Therapeutics Inc.INDUSTRY | 1 | Jul 1, 2015 | clinicaltrials |
| NCT00954941 | Ondansetron Versus Aprepitant Plus Ondansetron for Emesis | completed | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 25, 2015 | clinicaltrials |
| NCT00175812 | Differentiation Induction in Acute Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 24 | University of BergenOTHER | 1 | Jun 24, 2015 | clinicaltrials |
| NCT00995332 | Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine | completed | Phase 1 / Phase 2 | 36 | University of BergenOTHER | 1 | Jun 24, 2015 | clinicaltrials |
| NCT00990587 | Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy | completed | Phase 1 | 20 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT00957385 | Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients | completed | Phase 2 | 24 | University Health Network, TorontoOTHER | 1 | Jun 19, 2015 | clinicaltrials |
| NCT00034684 | Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701) | completed | Phase 1 / Phase 2 | 132 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 17, 2015 | clinicaltrials |
| NCT01041443 | 5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01344876 | Phase I Study of OPB-51602 in Patients With Hematologic Malignancies | completed | Phase 1 | 20 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 8, 2015 | clinicaltrials |
| NCT02461121 | HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk | completed | Phase 3 | 156 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT01795716 | Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body | completed | Phase 1 | 21 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 19, 2015 | clinicaltrials |
| NCT00678275 | Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia | completed | Phase 3 | 161 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 13, 2015 | clinicaltrials |
| NCT01146223 | Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia | completed | — | 10 | Children's Oncology GroupNETWORK | 1 | May 7, 2015 | clinicaltrials |
| NCT01149915 | Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias | completed | Phase 1 | 40 | Threshold PharmaceuticalsINDUSTRY | 1 | May 7, 2015 | clinicaltrials |
| NCT01220648 | Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)(NICOLI) | completed | Phase 1 | 4 | Novartis PharmaceuticalsINDUSTRY | 1 | May 5, 2015 | clinicaltrials |
| NCT02016833 | Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity | completed | — | 15 | PX BiosolutionsINDUSTRY | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00217646 | Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Apr 28, 2015 | clinicaltrials |
| NCT00383474 | Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT01332786 | Safety Study Evaluating Intravenous Infusions of Tigecycline to Treat Acute Myeloid Leukemia | completed | Phase 1 | 27 | University Health Network, TorontoOTHER | 2 | Apr 15, 2015 | clinicaltrials |
| NCT01361464 | Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Apr 8, 2015 | clinicaltrials |
| NCT00924443 | A Study of Clofarabine in Older Patients With Acute Myeloid Leukemia (AML) for Whom Chemotherapy Is Not Suitable | completed | Phase 2 | 69 | Genzyme, a Sanofi CompanyINDUSTRY | 3 | Apr 1, 2015 | clinicaltrials |
| NCT00098033 | Investigation of Clofarabine in Acute Leukemias | completed | Phase 2 | 64 | University of TexasOTHER | 0 | Mar 25, 2015 | clinicaltrials |
| NCT00990054 | Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 1 | 36 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 24, 2015 | clinicaltrials |
| NCT01819558 | Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy(ALLO-WT1) | completed | Phase 1 / Phase 2 | 2 | Institut Paoli-CalmettesOTHER | 1 | Mar 20, 2015 | clinicaltrials |
| NCT00088543 | Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant | completed | N/A | 60 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Mar 18, 2015 | clinicaltrials |
| NCT00656617 | Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | completed | Phase 2 | 106 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT01120457 | First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers | completed | Phase 1 | 96 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00343798 | A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies | completed | Phase 1 | 23 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 11, 2015 | clinicaltrials |
| NCT00528333 | A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML | completed | Phase 2 | 211 | Seagen Inc.INDUSTRY | 1 | Jan 7, 2015 | clinicaltrials |
| NCT00381550 | 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 6, 2015 | clinicaltrials |
| NCT00351975 | Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases | completed | Phase 1 | 56 | National Cancer Institute (NCI)NIH | 3 | Dec 23, 2014 | clinicaltrials |
| NCT00661180 | Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec(ORACLE) | completed | Phase 2 | 10 | BayerINDUSTRY | 2 | Dec 23, 2014 | clinicaltrials |
| NCT01132586 | Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 | 61 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00283114 | A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome | completed | Phase 1 | 82 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT00858806 | Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy(INTERIM0407) | completed | Phase 2 | 78 | Università degli Studi di BresciaOTHER | 1 | Dec 3, 2014 | clinicaltrials |
| NCT00703300 | Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Nov 7, 2014 | clinicaltrials |
| NCT00123487 | Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML | completed | Phase 3 | 638 | Bristol-Myers SquibbINDUSTRY | 32 | Nov 3, 2014 | clinicaltrials |
| NCT00322101 | Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia | completed | Phase 3 | 25 | Fred Hutchinson Cancer CenterOTHER | 2 | Oct 31, 2014 | clinicaltrials |
| NCT00408278 | Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) | completed | Phase 4 | 300 | PETHEMA FoundationOTHER | 3 | Oct 28, 2014 | clinicaltrials |
| NCT00504764 | Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) | completed | Phase 4 | 60 | PETHEMA FoundationOTHER | 1 | Oct 28, 2014 | clinicaltrials |
| NCT00602771 | Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia | completed | Phase 2 | 84 | National Cancer Institute (NCI)NIH | 1 | Oct 9, 2014 | clinicaltrials |
| NCT01910623 | Long-Term Quality of Life in Patients With Acute Promyelocytic Leukemia(QOL-APL0512) | completed | — | — | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Oct 2, 2014 | clinicaltrials |
| NCT01751919 | A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I) | completed | Phase 1 | 37 | Dong-A ST Co., Ltd.INDUSTRY | 1 | Oct 1, 2014 | clinicaltrials |
| NCT00074737 | Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML | completed | Phase 2 | 53 | Eleos, Inc.INDUSTRY | 1 | Sep 18, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Jul 28, 2015source: clinicaltrials